Litcius/Paper detail

Efficacy and Safety of Mirikizumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-2 Study.

Unknown authors

2022PubMed18 citationsOpen Access PDF

Topics & Concepts

Ulcerative colitisMedicineInternal medicineMaintenance therapyGastroenterologySurgeryDiseaseChemotherapyInflammatory Bowel DiseaseMicroscopic ColitisHelicobacter pylori-related gastroenterology studies
Efficacy and Safety of Mirikizumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-2 Study. | Litcius